Synendos Therapeutics expands Series A round

Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million.

Synendos Therapeutics, a biopharmaceutical company focused on treating central nervous system disorders, has expanded its Series A round to CHF 24 million. The expansion is a result of an investment made by Ysios Capital.

Source: Press Release